0001572426-15-000106.txt : 20150820 0001572426-15-000106.hdr.sgml : 20150820 20150820191556 ACCESSION NUMBER: 0001572426-15-000106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150820 FILED AS OF DATE: 20150820 DATE AS OF CHANGE: 20150820 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heffernan Mark CENTRAL INDEX KEY: 0001632439 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 151067325 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 00000 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-08-20 0001618561 Nexvet Biopharma plc NVET 0001632439 Heffernan Mark C/O NEXVET BIOPHARMA PLC NIBRT, FOSTERS AVENUE, MOUNT MERRION BLACKROCK L2 IRELAND 1 1 0 0 Chief Executive Officer Ordinary Shares 2015-08-20 4 A 0 4834 .125 A 12084 D Ordinary Shares 234383 I By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C> Option to Purchase Shares .125 2015-08-20 4 M 0 4834 0 D 2015-07-01 2019-07-01 Ordinary Shares 4834 16916 D The reporting person and his spouse share voting and dispositive power with respect to the reported securities. The option to purchase 4,834 shares vested on 7/1/15 and was exercised on 8/20/15; the option to purchase 4,833 shares will vest and become exercisable on each of 7/1/16 and 7/1/17. The option to purchase the remaining 7,250 shares will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors; such completion must occur on or before 7/1/19. /s/ Mark Heffernan by Geraldine Farrell, Attorney-in-Fact 2015-08-20